<table>
<thead>
<tr>
<th>Short Name</th>
<th>Comments</th>
<th>Type</th>
<th>Investigator</th>
<th>Contact</th>
</tr>
</thead>
</table>
| BMT Cord Blood Access Protocol | A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) in Pediatric and Adult Patients with Hematologic Malignancies and other Indications  
This is an access study in which umbilical cord blood used for bone marrow transplant is only available through this access and distribution study. In October 2011, the Food and Drug Administration (FDA) began considering cord blood as a biological drug. In the United States, drugs must meet standards set by the FDA to make sure they are safe. Cord blood units that were not collected, tested, or stored exactly according to FDA standards may be used for transplant if the transplant is done as part of a study.  
For More Information | Symptom Management                                                      | Dr. Troy Quigg    | Laura Paulsen  
Laura.Paulsen@spectrumhealth.org  
616.486.6125 |
| NYBB UCB          | A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients | Treatment         | Dr. Troy Quigg    | Laura Paulsen  
Laura.Paulsen@spectrumhealth.org  
616.486.6125 |
| BMT CTN 1507      | Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease  
This is a Phase II, single arm, multi-center trial, designed to estimate the efficacy and toxicity of haploidentical bone marrow transplantation (BMT) in patients with sickle cell disease (SCD). Based on their age and entry criteria patients are stratified into two groups: (1) children with SCD with strokes; and (2) adults with severe SCD.  
For more information... | Treatment         | Dr. Ulrich Duffner | Laura Paulsen  
Laura.Paulsen@spectrumhealth.org  
616.486.6125 |
| ENDRAD            | The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL | Treatment         | Dr. Ulrich Duffner | Laura Paulsen  
Laura.Paulsen@spectrumhealth.org  
616.486.6125 |
Hematology/Oncology/BMT

This study will evaluate the use of non-TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regimen as part of the treatment cohort of the study. Subjects who are pre-HCT NGS-MRD positive will be treated as per treating center standard and will be foll

For more information...